Reference pricing models are emerging as increasingly popular approaches for lowering drug costs.
David Henka
Advertisement
Articles by David Henka
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
TKI axitinib beats anti-VEGF therapy in wet AMD in phase 3 trial | ASRS 2026
2
FDA approves Lipfendra, first oral PCSK9 inhibitor
3
Bevacizumab surpasses Eylea as the most common retinal disease injection | ASRS 2026
4
Phase 3 trial confirms efficacy of tarcocimab in diabetic retinopathy | ASRS 2026
5